NeuroEM
NeuroEM develops a non-invasive medical device for treating cognitive decline and Alzheimer's disease using Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF). The company's patented wearable device, MemorEM, delivers electromagnetic treatment that breaks up beta-amyloid and p-tau proteins, the toxic proteins at the root of Alzheimer's disease. NeuroEM is the first company to receive FDA…
Funding snapshot
About
NeuroEM develops a non-invasive medical device for treating cognitive decline and Alzheimer's disease using Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF). The company's patented wearable device, MemorEM, delivers electromagnetic treatment that breaks up beta-amyloid and p-tau proteins, the toxic proteins at the root of Alzheimer's disease. NeuroEM is the first company to receive FDA Breakthrough Device status for treating Alzheimer's disease, offering a technology-driven alternative to pharmaceutical approaches. The treatment originated from a laboratory discovery where electromagnetic frequencies unexpectedly showed therapeutic effects on toxic brain proteins. Founded in 2013 and headquartered in Tampa, Florida, NeuroEM has raised approximately $9 million in Series A funding from investors including Bluelake, HHS, and New York Angels.
Business model
Wearable Technology > Health and Wellness Devices > Neural,
Disease Self Management > Neurological Disorders > Therapy > Cognitive Training > Device > Wearable,
Neurology > Medical Devices > Therapeutic Devices > Neurodegenerative > Alzheimer Disease
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.